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Liver disease represents 2-3% of all deaths globally1. In the UK, mortality rates have increased by 
400% since 1970 and one million hospital admissions a year are alcohol-related, causing costs to the 
NHS of £3.5 billion2. Patients developing liver failure are termed acute decompensation (AD) or 
acute-on-chronic liver failure3. They are highly prone to bacterial infection secondary to immune 
dysfunction4, with nosocomial (hospital-acquired) infection rates of 35% compared to 5% in other 
hospital inpatients without cirrhosis5. In the absence of immune restorative therapies we “coat” our 
patients in antibiotics in order to prevent infections. A Cochrane review concluded appropriate 
empiric antibiotic treatment may reduce mortality in certain circumstances, e.g. following acute 
upper gastrointestinal bleeding in patients with very severe liver disease6. However, these data, 
from largely single centre studies, have been applied to all liver patients, even those without 
significant disease, leading to widespread over-prescription7. Cirrhosis patients represent a 
particularly high risk for AMR as they are frequently prescribed antibiotics, undergo many invasive 
procedures and have recurrent hospital admissions encouraging both increased AMR rates and 
spread of resistant pathogens. This has led to a substantial reduction in empirical antibiotic 
treatment efficacy with MDR bacteria resistant to 60% of recommended drugs prevalent in certain 
countries7. There is the very real threat that we will face a future in which antibiotics no longer work. 
Governmental-industry initiatives are developing new antibiotics and novel strategies to address 
AMR (e.g. COMBACTE). Whether these will cope with rising rates of AMR is moot. As antibiotic 
resistance is a direct consequence of their use, the crucial strategy must be sound antimicrobial 
stewardship.  
Microbiology culture represents the current gold standard for diagnosis of bacterial infection but 
results take 24-48hrs which is considered too long to wait by clinicians. In the meantime almost 
every cirrhosis patient suspected of infection will be commenced on broad spectrum empirical 
treatment. Furthermore these cultures are positive in only 40-50% of those treated but most 
clinicians agree that cirrhosis infection rates are much higher (more like 65%) and therefore 
antibiotics are continued in many for 7-10 days even culture negative patients. It is considered that 
this over-prescription has increased antimicrobial resistance (AMR) rates, in turn leading to an 
increase in empirical antibiotic treatment failure, with 11-45% of spontaneous bacterial peritonitis 
(SBP) patients now culturing bacteria resistant to first line empirical choices7. The importance of 
correctly selecting the first line antibiotic is underlined by data in cirrhosis and septic shock showing 
that each hour of delay in appropriate antimicrobial therapy was associated with an almost doubling 
of hospital mortality8. Hepatologists faced with the dilemma of whether to escalate 
empirical/prophylactic treatment to “antibiotics of last resort” (e.g. Meropenem) or to restrict 
antibiotic use with potential unfavourable consequences often choose the former, perpetuating the 
vicious cycle leading to further resistance and increased empirical treatment failure. Evidently we 
need to improve our choice of first line treatment and restrict unnecessary antibiotic use, however 
in order to do so we need more precise diagnostics. 
Industry rapid diagnostic platforms e.g. from Biocartis and Abbott have been developed. These 
techniques examine pathogen DNA using real-time PCR to detect bacteria from 5 ml of body fluid. 
The Abbot system, IRIDICA demonstrated an increase in pathogen identification over standard blood 
cultures (37% vs 11%)9. Although these data suggest that we may fail to identify bacteria in a 
significant number of patients, the clinical significance of these pathogens remains undetermined. 
This may be even more difficult to interpret in cirrhosis patients because of increased gut bacterial 
translocation into the systemic circulation. Furthermore this system takes 6 hours. The Biocartis 
platforms offers potential for (near) point-of-care systems within 3-5 years, results within 60-90 
minutes, albeit with more restricted pathogen panels. A strategy focusing on host response 
biomarkers to complement pathogen detection may yield important data. Serial procalcitonin 
measurements are being used increasingly in sepsis, although values alter with hepatic dysfunction 
and specific gene expression infection bio-signatures have also been developed in sepsis. There may 
be scope to apply to these approaches in cirrhosis. 
We also need to develop non-antibiotic strategies targeting gut-bacterial translocation in order to 
prevent infection. Oral probiotics, live microorganisms, have been shown to reduce intestinal 
permeability and reduce bacterial translocation. However these findings have not translated into 
meaningful clinical effects and caution is warranted given the increased mortality in a randomised 
controlled trial of probiotics given for acute pancreatitis10. A further possibility is Fecal microbiota 
transplant which involves infusion of healthy donor stool into a patient’s intestine with the goal of 
rebalancing normal intestinal microbiota. This can reverse intestinal colonisation with multi-drug 
resistant organisms e.g. extended-spectrum beta-lactamase producing E.coli.11, however data in 
cirrhosis is limited. Non selective Beta-Blockers used to treat portal hypertension have been 
associated with a reduction in bacterial translocation. However clinical data regarding infection 
prevention is conflicting with two retrospective studies demonstrating a lack of effect and one 
Meta–analysis in favour of SBP prevention7. Statins have been proposed to improve host immune 
defence and a recent retrospective cohort study in patients with compensated cirrhosis concluded 
that there was a decrease in severe bacterial infections in statin users with a hazard ratio of 0.4212. 
Finally experiment evidence exists for a beneficial immune effect following 20% Human Albumin 
Solution infusions4 and large scale RCTs are in progress. We await formal prospective clinical trials of 
these agents. 
In the longer term hepatologists, infectious disease specialists, microbiologists, epidemiologists and 
industry must work together to improve treatment of bacterial infection in cirrhosis, to preserve the 
lifespan of our antibiotics and to prevent a future in which patients die for lack of effective therapy. 
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